Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H29ClN6O2 |
Molecular Weight | 505.011 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C=NN1C2=CC=C(Cl)C=C2)C(=O)NC3=CC(C#N)=C(C=C3)N4CCC(CC4)N5CCOCC5
InChI
InChIKey=BWZNJVZTAWBIFG-UHFFFAOYSA-N
InChI=1S/C27H29ClN6O2/c1-19-25(18-30-34(19)24-5-2-21(28)3-6-24)27(35)31-22-4-7-26(20(16-22)17-29)33-10-8-23(9-11-33)32-12-14-36-15-13-32/h2-7,16,18,23H,8-15H2,1H3,(H,31,35)
Molecular Formula | C27H29ClN6O2 |
Molecular Weight | 505.011 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17984577
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17984577
Interleukin (IL)-15 and IL-17 are thought to play an important role in the pathogenesis of rheumatoid arthritis (RA) because both pro-inflammatory cytokines are found in synovial fluid of RA patients. Y-320 is an orally active a new phenylpyrazoleanilide immunomodulator which inhibits IL-17 production by CD4 T cells stimulated with IL-15, providing a useful therapy for RA.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P40933 Gene ID: 3600.0 Gene Symbol: IL15 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24366113 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17984577
in mice: 0.3 to 3 mg/kg orally
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24366113
In human peripheral blood CD4 T cells, a significant level of IL-17 was produced by stimulation with rh-IL-15 (3 to 100 ng/mL). Y-320 (10 to 300 nM) significantly inhibited IL-17 production by human CD4 T cells stimulated with rh-IL-15 (100 ng/mL) with an IC50 value of 57.4 nM. These results clearly indicate that Y-320 inhibits IL-17 production from human CD4 T cells including Th17 cells and memory type CD4 T cells stimulated with IL-15.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:13:25 GMT 2023
by
admin
on
Sat Dec 16 17:13:25 GMT 2023
|
Record UNII |
82S7NR4B46
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
82S7NR4B46
Created by
admin on Sat Dec 16 17:13:25 GMT 2023 , Edited by admin on Sat Dec 16 17:13:25 GMT 2023
|
PRIMARY | |||
|
DTXSID101031899
Created by
admin on Sat Dec 16 17:13:25 GMT 2023 , Edited by admin on Sat Dec 16 17:13:25 GMT 2023
|
PRIMARY | |||
|
288250-47-5
Created by
admin on Sat Dec 16 17:13:25 GMT 2023 , Edited by admin on Sat Dec 16 17:13:25 GMT 2023
|
PRIMARY | |||
|
Y-320
Created by
admin on Sat Dec 16 17:13:25 GMT 2023 , Edited by admin on Sat Dec 16 17:13:25 GMT 2023
|
PRIMARY | |||
|
22227931
Created by
admin on Sat Dec 16 17:13:25 GMT 2023 , Edited by admin on Sat Dec 16 17:13:25 GMT 2023
|
PRIMARY |